Waddill William D.
Insider CIK 1553338 · OMED SVP & Chief Financial Officer · PTGX Director · CALA SR. VP & CFO · ANNX Director · TSBX Director · ARWR Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-06-23 | 2026-06-25 | 9,000 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-06-23 | 2026-06-25 | 9,000 | $117.94 | $1.06M | 7,825 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-06-23 | 2026-06-25 | 9,000 | $16.54 | $148.9K | 16,825 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2026-06-11 | 2026-06-15 | 65,000 | — | $0 | 65,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-06-10 | 2026-06-11 | 6,000 | — | $0 | 9,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-06-10 | 2026-06-11 | 3,000 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-06-10 | 2026-06-11 | 6,000 | $16.54 | $99.2K | 16,825 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-06-10 | 2026-06-11 | 9,000 | $107.68 | $969.1K | 7,825 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-06-10 | 2026-06-11 | 3,000 | $11.80 | $35.4K | 10,825 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-05-29 | 2026-06-01 | 9,000 | — | $0 | 3,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-05-29 | 2026-06-01 | 9,000 | $11.80 | $106.2K | 16,825 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-05-29 | 2026-06-01 | 9,000 | $99.64 | $896.8K | 7,825 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2026-02-06 | 2026-02-06 | 20,000 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2026-02-06 | 2026-02-06 | 20,000 | $83.68 | $1.67M | 7,825 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2026-02-06 | 2026-02-06 | 20,000 | $8.31 | $166.2K | 27,825 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2026-01-02 | 2026-01-06 | 3,762 | — | $0 | 3,762 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2026-01-02 | 2026-01-06 | 2,695 | — | $0 | 7,825 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2025-12-19 | 2025-12-23 | 500 | $68.53 | $34.3K | 56,563 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2025-12-19 | 2025-12-23 | 2,416 | $66.66 | $161.1K | 62,514 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2025-12-19 | 2025-12-23 | 5,451 | $68.01 | $370.7K | 57,063 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2025-12-16 | 2025-12-18 | 7,819 | — | $0 | 64,930 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2025-10-10 | 2025-10-14 | 12,000 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-10-10 | 2025-10-14 | 4,000 | $69.25 | $277.0K | 13,130 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2025-10-10 | 2025-10-14 | 12,000 | $6.98 | $83.8K | 17,130 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-10-10 | 2025-10-14 | 8,000 | $87.81 | $702.5K | 5,130 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-09-22 | 2025-09-24 | 4,000 | $64.25 | $257.0K | 5,130 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-08-27 | 2025-08-29 | 4,000 | $59.25 | $237.0K | 9,130 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2025-06-05 | 2025-06-09 | 55,000 | — | $0 | 55,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2025-03-17 | 2025-03-19 | 4,000 | $54.25 | $217.0K | 13,130 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2025-01-02 | 2025-01-06 | 6,584 | — | $0 | 6,584 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award | 2025-01-02 | 2025-01-06 | 5,130 | — | $0 | 17,130 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2024-12-18 | 2024-12-20 | 16,733 | $22.99 | $384.7K | 57,111 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2024-12-17 | 2024-12-18 | 3,747 | $22.04 | $82.6K | 40,378 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2024-12-16 | 2024-12-18 | 3,748 | $21.90 | $82.1K | 44,125 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2024-09-10 | 2024-09-12 | 8,000 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2024-09-10 | 2024-09-12 | 8,000 | $12.88 | $103.0K | 20,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-09-10 | 2024-09-12 | 8,000 | $45.00 | $360.0K | 12,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2024-07-24 | 2024-07-26 | 8,000 | — | $0 | 8,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2024-07-24 | 2024-07-26 | 8,000 | $12.88 | $103.0K | 20,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-07-24 | 2024-07-26 | 8,000 | $40.00 | $320.0K | 12,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2024-06-07 | 2024-06-11 | 8,000 | — | $0 | 16,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-06-07 | 2024-06-11 | 8,000 | $35.00 | $280.0K | 12,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2024-06-07 | 2024-06-11 | 8,000 | $12.88 | $103.0K | 20,000 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2024-06-05 | 2024-06-07 | 44,000 | — | $0 | 44,000 | SEC↗ |
| TSBX Turnstone Biologics Corp. | A Award deriv | 2024-06-03 | 2024-07-02 | 12,770 | — | $0 | 12,770 | SEC↗ |
| TSBX Turnstone Biologics Corp. | A Award deriv | 2024-04-15 | 2024-04-16 | 25,540 | — | $0 | 25,540 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2024-03-01 | 2024-03-01 | 12,975 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2024-03-01 | 2024-03-01 | 12,975 | $6.09 | $79.0K | 24,975 | SEC↗ |
| PTGX Protagonist Therapeutics, | S Sale | 2024-03-01 | 2024-03-01 | 12,975 | $31.34 | $406.6K | 12,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2024-01-11 | 2024-01-16 | 2,634 | $37.81 | $99.6K | 49,170 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2024-01-11 | 2024-01-16 | 1,300 | $38.59 | $50.2K | 47,870 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2024-01-02 | 2024-01-04 | 25,700 | — | $0 | 25,700 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2023-12-15 | 2023-12-19 | 14,987 | $25.41 | $380.8K | 51,804 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2023-06-08 | 2023-06-12 | 24,000 | — | $0 | 24,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2023-01-16 | 2023-01-18 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award deriv | 2023-01-10 | 2023-01-11 | 4,593 | — | $0 | 4,593 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2023-01-10 | 2023-01-11 | 7,867 | — | $0 | 36,817 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2023-01-09 | 2023-01-11 | 3,200 | $30.00 | $96.0K | 28,950 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2022-06-09 | 2022-06-13 | 24,000 | — | $0 | 24,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2022-05-26 | 2022-05-27 | 20,000 | — | $0 | 20,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise deriv | 2022-05-03 | 2022-05-04 | 12,000 | — | $0 | 0 | SEC↗ |
| PTGX Protagonist Therapeutics, | M Exercise | 2022-05-03 | 2022-05-04 | 12,000 | $8.59 | $103.1K | 12,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2022-01-07 | 2022-01-07 | 6,400 | — | $0 | 32,150 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2022-01-03 | 2022-01-04 | 2,128 | $65.01 | $138.3K | 26,022 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2022-01-03 | 2022-01-04 | 272 | $66.25 | $18.0K | 25,750 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2022-01-03 | 2022-01-04 | 2,100 | $64.23 | $134.9K | 28,150 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2021-08-12 | 2021-08-16 | 20,000 | — | $0 | 20,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2021-05-27 | 2021-05-28 | 18,000 | — | $0 | 18,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2021-01-04 | 2021-01-05 | 3,750 | $76.08 | $285.3K | 30,250 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2021-01-01 | 2021-01-05 | 9,000 | — | $0 | 34,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2020-12-10 | 2020-12-11 | 1,200 | $68.50 | $82.2K | 26,800 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2020-12-10 | 2020-12-11 | 1,800 | $73.10 | $131.6K | 25,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2020-05-28 | 2020-05-29 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2020-05-11 | 2020-05-13 | 26,000 | $36.54 | $950.0K | 28,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2020-01-01 | 2020-01-03 | 7,500 | — | $0 | 54,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2019-06-07 | 2019-06-11 | 12,000 | — | $0 | 12,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | S Sale | 2019-01-11 | 2019-01-11 | 8,500 | $14.77 | $125.5K | 46,500 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2019-01-01 | 2019-01-03 | 30,000 | — | $0 | 55,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2018-05-29 | 2018-06-12 | 12,000 | — | $0 | 12,000 | SEC↗ |
| ARWR ARROWHEAD PHARMACEUTICALS, | A Award | 2018-01-01 | 2018-01-03 | 25,000 | — | $0 | 25,000 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2017-05-25 | 2017-05-26 | 12,000 | — | $0 | 12,000 | SEC↗ |
| CALA Calithera Biosciences, Inc | A Award deriv | 2016-11-29 | 2016-12-01 | 75,000 | — | $0 | 75,000 | SEC↗ |
| CALA Calithera Biosciences, Inc | J Other | 2016-09-29 | 2016-10-03 | 17,485 | — | $0 | 17,485 | SEC↗ |
| PTGX Protagonist Therapeutics, | A Award deriv | 2016-09-13 | 2016-09-15 | 24,000 | — | $0 | 24,000 | SEC↗ |
| CALA Calithera Biosciences, Inc | A Award deriv | 2016-01-19 | 2016-01-21 | 70,000 | — | $0 | 70,000 | SEC↗ |
| CALA Calithera Biosciences, Inc | M Exercise deriv | 2015-07-14 | 2015-07-16 | 13,125 | — | $0 | 61,880 | SEC↗ |
| CALA Calithera Biosciences, Inc | M Exercise | 2015-07-14 | 2015-07-16 | 13,125 | $2.64 | $34.6K | 15,625 | SEC↗ |
| CALA Calithera Biosciences, Inc | A Award deriv | 2015-02-11 | 2015-02-12 | 45,000 | — | $0 | 45,000 | SEC↗ |
| CALA Calithera Biosciences, Inc | M Exercise deriv | 2014-12-16 | 2014-12-18 | 5,626 | — | $0 | 75,005 | SEC↗ |
| CALA Calithera Biosciences, Inc | M Exercise deriv | 2014-12-16 | 2014-12-18 | 1,171 | — | $0 | 17,569 | SEC↗ |
| CALA Calithera Biosciences, Inc | M Exercise | 2014-12-16 | 2014-12-18 | 5,626 | $2.64 | $14.9K | 15,001 | SEC↗ |
| CALA Calithera Biosciences, Inc | M Exercise | 2014-12-16 | 2014-12-18 | 1,171 | $7.20 | $8.4K | 16,172 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion deriv | 2013-07-23 | 2013-07-23 | 5,159 | — | $0 | 0 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | C Conversion | 2013-07-23 | 2013-07-23 | 5,159 | — | $0 | 29,758 | SEC↗ |
| OMED OncoMed Pharmaceuticals In | A Award deriv | 2013-07-17 | 2013-07-19 | 14,000 | — | $0 | 14,000 | SEC↗ |